Savale Laurent, Chaumais Marie-Camille, O'Connell Caroline, Humbert Marc, Sitbon Olivier
aUniversity Paris-Sud, Faculté de Médecine, Université Paris-Saclay bAP-HP, Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre cINSERM UMR_S 999, Hôpital Marie Lannelongue dFaculté de Pharmacie, University Paris-Sud eAP-HP, Service de Pharmacie, DHU Thorax Innovation, Hôpital Antoine Béclère, Paris, France.
Curr Opin Pulm Med. 2016 Sep;22(5):415-20. doi: 10.1097/MCP.0000000000000307.
Pulmonary adverse effects of interferon (IFN) therapies are rare but can be life threatening. This article proposes to review clinical and experimental data suggesting a causal link between interferon exposure and pulmonary arterial hypertension (PAH).
Interferon has recently been added to the list of possible risk factors for PAH. This was justified by the reporting of many cases of pulmonary hypertension potentially associated with IFN-α or IFN-β exposure. Some of them were reversible after cessation of interferon exposure, especially in patients without concomitant risk factors for pulmonary hypertension. In contrast, it remains a challenge to definitively confirm the causal role of IFN-α in patients treated for hepatitis C viral infection because of frequent concomitant PAH risk factors such as portal hypertension and/or HIV infection. In these patients, temporal and clinical arguments suggest that interferon may potentially act as an additional trigger for PAH. Moreover, the information obtained from clinical experience with interferon therapy has been enriched by basic science research on this topic suggesting that interferon is involved in both human and experimental pulmonary hypertension.
Many clinical and experimental data corroborate the link between interferon exposure and the risk to develop PAH.
干扰素（IFN）治疗的肺部不良反应虽罕见，但可能危及生命。本文旨在综述临床和实验数据，以表明干扰素暴露与肺动脉高压（PAH）之间存在因果关系。
干扰素最近被列入PAH的可能危险因素清单。这是基于许多可能与IFN-α或IFN-β暴露相关的肺动脉高压病例报告而得出的。其中一些在停止干扰素暴露后是可逆的，尤其是在没有肺动脉高压伴随危险因素的患者中。相比之下，由于丙型肝炎病毒感染患者中频繁存在门静脉高压和/或HIV感染等PAH伴随危险因素，因此明确证实IFN-α在这些患者中的因果作用仍然是一项挑战。在这些患者中，时间和临床证据表明干扰素可能潜在地作为PAH的额外触发因素。此外，关于这一主题的基础科学研究丰富了从干扰素治疗临床经验中获得的信息，表明干扰素与人类和实验性肺动脉高压均有关联。
许多临床和实验数据证实了干扰素暴露与发生PAH风险之间的联系。
